Journal of Inherited Metabolic Disease

, Volume 37, Issue 6, pp 969–978 | Cite as

Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study

  • L. J. Anderson
  • K. M. Wyatt
  • W. Henley
  • V. Nikolaou
  • S. Waldek
  • D. A. Hughes
  • G. M. Pastores
  • S. Logan
Original Article



To determine the effectiveness of enzyme replacement therapy (ERT) for adults and children with Fabry disease.


Cohort study including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment and untreated patients contributed natural history data.


Consenting adults (N = 289) and children (N = 22) with a confirmed diagnosis of Fabry disease attending a specialist Lysosomal Storage Disorder treatment centre in England. At recruitment 211 adults and seven children were on ERT (range of treatment duration, 0 to 9.7 and 0 to 4.2 years respectively).

Outcome measures

Clinical outcomes chosen to reflect disease progression included left ventricular mass index (LVMI); proteinuria; estimated glomerular filtration rate (eGFR); pain; hearing and transient ischaemic attacks (TIA)/stroke.


We found evidence of a statistically significant association between time on ERT and a small linear decrease in LVMI (p = 0.01); a reduction in the risk of proteinuria after adjusting for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (p < 0.001) and a small increase in eGFR in men and women without pre-treatment proteinuria (p = 0.01 and p < 0.001 respectively). The same analyses in children provided no statistically significant results. No associations between time on ERT and pain, risk of needing a hearing aid, or risk of stroke or TIAs, were found.


These data provide some further evidence on the long-term effectiveness of ERT in adults with Fabry disease, but evidence of effectiveness could not be demonstrated in children.


Proteinuria Enzyme Replacement Therapy Fabry Disease Leave Ventricular Mass Index Transient Ischaemic Attack 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank study site personnel Marie Meehan, Andrea Hill, Debbie Hugh, Sarah West, Sandhya Maddukuri, Kate Blackler, Hannah Russon, Navneeta Reddy, Jennifer Hutchinson, Nike Aina and Noura Hamdi for their hard work in the recruitment of patients to this study, and in managing the patients’ data at each of the seven sites. We thank the late Ed Wraith, Robin Lachmann, Atul Mehta, Ashok Vellodi, Patrick Deegan, Tim Cox, Chris Hendriksz, Philip Lee, Uma Ramaswami, Simon Jones and Tanya Collin-Histed for their contribution to the design and conduct of the study. Thanks to Rob Anderson for his contribution to the design of the study and data collection forms, to Sheena Oxer and Louise Klinger for their contribution to the set-up and coordination of the study, and to Laura Cocking for her help in the design and the management of the databases throughout the study.

We are grateful to all members of the LSD patient support groups and the Trial Steering Committee. Finally, special thanks to the patients and their families who allowed us to collect information from their hospital records and gave their time to complete the questionnaires. We thank them for their invaluable contribution.

Compliance with ethics guidelines

Conflicts of interest

Lindsey Anderson, Katrina Wyatt, William Henley, Vasilis Nikolaou and Stuart Logan declare that they have no conflicts of interest.

Stephen Waldek is a member of the Fabry Registry Board and the Fabry Expert Group and has received funding for research, and honoraria for lectures and consultancy on research studies from Shire HGT and Genzyme. He has also received research grants from Biomarin, Synageva and Amicus.

Derralynn Hughes has received funding for research and travel to meetings, honoraria for lectures and consultancy projects or advisory boards from Shire HGT, Genzyme, Amicus, Actelion, and Biomarin. Consultancy and advisory board work is administered via UCL business and used in part to fund research.

Gregory M. Pastores has received funding for research and travel to meetings, honoraria for lectures and consultancy projects or advisory boards from Shire HGT, Genzyme, Amicus, Actelion, and Biomarin.

Informed consent

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients before being included in the study.

Supplementary material

10545_2014_9717_MOESM1_ESM.docx (36 kb)
ESM 1 (DOCX 36 kb)


  1. Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV (2012) Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol 35(4 (suppl)):947–954Google Scholar
  2. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86PubMedCrossRefGoogle Scholar
  3. Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34(12):838–844PubMedCrossRefGoogle Scholar
  4. Connock M, Juarez-Garcia A, Frew E, et al (2006) A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 10(20): iii-iv, ix-113Google Scholar
  5. Desnick RJ, Wasserstein MP (2001) Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp 31:317–339PubMedGoogle Scholar
  6. Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57(6):450–458PubMedCrossRefGoogle Scholar
  7. El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663PubMedGoogle Scholar
  8. Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68(3):711–722PubMedCrossRefPubMedCentralGoogle Scholar
  9. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547–1557PubMedCrossRefGoogle Scholar
  10. Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A (2003) Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26(8):787–794PubMedCrossRefGoogle Scholar
  11. Henley W, Anderson LJ, Wyatt KM, Nikolaou V, Anderson R, Logan S (2014) The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders. JIMD Rep (in press) Google Scholar
  12. Hoffmann B, Reinhardt D, Koletzko B (2004) Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur J Gastroenterol Hepatol 16(10):1067–1069PubMedCrossRefGoogle Scholar
  13. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23(6):535–542PubMedCrossRefGoogle Scholar
  14. Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153–158PubMedCrossRefGoogle Scholar
  15. Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108PubMedCrossRefGoogle Scholar
  16. Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247–254PubMedCrossRefGoogle Scholar
  17. Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatrica 94(s447):24–27PubMedCrossRefGoogle Scholar
  18. Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242PubMedCrossRefGoogle Scholar
  19. Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRefGoogle Scholar
  20. Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2:4PubMedCrossRefPubMedCentralGoogle Scholar
  21. Motwani M, Banypersad S, Woolfson P, Waldek S (2012) Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 107(1–2):197–202PubMedCrossRefGoogle Scholar
  22. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47PubMedCrossRefPubMedCentralGoogle Scholar
  23. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis : Effectiveness of ERT in different disease stages. J Inherit Metab Dis (in press)Google Scholar
  24. Schafer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25(4):412PubMedCrossRefGoogle Scholar
  25. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749PubMedCrossRefGoogle Scholar
  26. Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111PubMedCrossRefPubMedCentralGoogle Scholar
  27. Schiffmann R, Martin RA, Reimschisel T et al (2010) Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 156(5):832–837, 837 e831PubMedCrossRefGoogle Scholar
  28. Schwartz GJ, Munoz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637PubMedCrossRefPubMedCentralGoogle Scholar
  29. Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40(3):788–794PubMedCrossRefGoogle Scholar
  30. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483PubMedCrossRefGoogle Scholar
  31. Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24(1):137–148PubMedCrossRefGoogle Scholar
  32. Vedder AC, Linthorst GE, Houge G et al (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2(7):e598PubMedCrossRefPubMedCentralGoogle Scholar
  33. Wanner C, Oliveira JP, Ortiz A et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5(12):2220–2228PubMedCrossRefPubMedCentralGoogle Scholar
  34. Warnock DG, Ortiz A, Mauer M et al (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27(3):1042–1049PubMedCrossRefPubMedCentralGoogle Scholar
  35. Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524–529PubMedCrossRefGoogle Scholar
  36. Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274(4):331–341PubMedCrossRefGoogle Scholar
  37. Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry Disease. Am J Hum Genet 75:65–74PubMedCrossRefPubMedCentralGoogle Scholar
  38. Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128PubMedCrossRefGoogle Scholar
  39. Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152(4):563–570, 570 e561PubMedCrossRefGoogle Scholar
  40. Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16(39):1–543PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • L. J. Anderson
    • 1
  • K. M. Wyatt
    • 1
  • W. Henley
    • 1
  • V. Nikolaou
    • 1
  • S. Waldek
    • 2
  • D. A. Hughes
    • 3
  • G. M. Pastores
    • 4
  • S. Logan
    • 1
  1. 1.Institute of Health ResearchUniversity of Exeter Medical SchoolExeterUK
  2. 2.Independent Medical Consultant, Retired Metabolic PhysicianFormerly of Salford Royal NHS Foundation TrustSalfordUK
  3. 3.Department of Haematology, Royal Free CampusUniversity CollegeLondonUK
  4. 4.Department of Medicine/National Centre for Inherited Metabolic DisordersMater Misericordiae University HospitalDublin 7Ireland

Personalised recommendations